BRISBANE, 3 JUNE 2013: Australian drug development company Invion Limited (ASX: IVX) is pleased to release a copy of the presentation that Managing Director and CEO, Dr Greg Collier will deliver this week during investor meetings in Singapore and Hong Kong, and to the AsiaBiotech Invest conference.
The conference presentation will occur on Wednesday 5 June at 12:05pm, local time at the Sheraton Hotel and Towers, Hong Kong.
Dr Collier will provide an overview of the Company’s current activities, including:
- phase II clinical trials of INV102 (nadolol) in asthma and chronic bronchitis;
- the phase II development of INV103 (ala-Cpn10) as a potential therapy for lupus; and,
- Invion’s expected value drivers over the next 12 – 36 months
Information about the AsiaBiotech Invest 2013 conference can be found at http://asiabiotechinvest.com.